Siemens Healthineers AG

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Siemens Healthineers AG operates as a holding company. The company intends to operate the digital services business. It operates through the following business segments: Imaging, Diagnotics, and Advanced Therapies. The Imaging segment offers diagnostic imaging products and a broad portfolio of advanced imaging and ultrasound systems and solutions. The Diagnostics segment offers products, services and solutions, including a broad array of testing applications, in the areas of laboratory, point of care and molecular diagnostics. The Advanced Therapies is a supplier of advanced therapy products, services and solutions to the therapy departments of healthcare providers. The company was founded on December 1, 2017 and is headquartered in Erlangen, Germany.

Siemens Healthineers has seen a 7.5% increase in its stock price since the last article and has a solid upside potential. The company's recent results show strong revenue growth, margin improvements, and successful contract wins. While the valuation of the company has increased, it still presents a potential double-digit annualized return for investors.

Siemens Healthineers: Good Return, Long-Term Potential Intact

Siemens Healthineers AG (SEMHF) Q1 2024 Earnings Call Transcript

Varian Medical Systems

German medical equipment maker Siemens Healthineers on Thursday posted first-quarter revenue above expectations and an operating result in line with consensus, driven by its U.S. cancer treatment unit Varian.

Siemens Healthineers Q1 sales beat expectations on strong Varian unit

Siemens Healthineers reported strong 4Q23 results with revenue growth of 11% and adjusted EBIT growth of 16%. The company aims to achieve double-digit EPS growth by 2025 and beyond through expansion in new areas and geographies. Despite a slight premium in valuation, the company has the potential to generate a significant rate of return for investors.

Siemens Healthineers: Strong Return, Still A 'Buy'

Siemens Healthineers AG (OTCPK:SEMHF) Q4 2023 Earnings Conference Call November 8, 2023 2:00 AM ET Company Participants Marc Koebernick - Investor Relations Bernd Montag - Chief Executive Officer Jochen Schmitz - Chief Financial Officer Conference Call Participants Graham Doyle - UBS Veronika Dubajova - Citi David Adlington - JPMorgan Hassan Al-Wakeel - Barclays Odysseas Manesiotis - Berenberg Robert Davies - Morgan Stanley Lisa Clive - Bernstein Richard Felton - Goldman Sachs Dylan van Haaften - Stifel Hugo Solvet - Exane Sezgi Ozener - HSBC Oliver Metzger - Oddo Falko Friedrichs - Deutsche Bank Operator Good morning, ladies and gentlemen, and welcome to Siemens Healthineers Conference Call. As a reminder, this conference is being recorded.

Siemens Healthineers AG (SEMHF) Q4 2023 Earnings Call Transcript

Siemens Healthineers on Wednesday posted better than expected fourth-quarter results helped by its cancer care unit and proposed an unchanged dividend for its fiscal year 2023.

Siemens Healthineers posts forecast beating Q4 results

Healthineers, a healthcare company formerly part of Siemens, offers potential market-beating upside. The company's main segments include imaging, diagnostics, advanced therapies, and Varian. Despite challenges from cost inflation and macro factors, Healthineers' solid company-wide results make it an appealing investment opportunity.

Siemens Healthineers: The Decline Makes The Upside Better

Siemens Healthineers AG (OTCPK:SEMHF) Q3 2023 Earnings Conference Call August 2, 2023 2:00 AM ET Company Participants Marc Koebernick - Head of Investor Relations Bernhard Montag - Chief Executive Officer Jochen Schmitz - Chief Financial Officer Conference Call Participants Hassan Al-Wakeel - Barclays Veronika Dubajova - Citi Graham Doyle - UBS David Adlington - JPMorgan Odysseas Manesiotis - Berenberg Robert Davies - Morgan Stanley Operator Good morning, ladies and gentlemen, and welcome to Siemens Healthineers Conference Call. As a reminder, this conference is being recorded.

Siemens Healthineers AG (SEMHF) Q3 2023 Earnings Call Transcript

U.S.-German medical device maker Siemens Healthineers on Wednesday reported a drop in quarterly operating profit and free cash flow due to the tailing-off of its rapid COVID-19 antigen test business.

Siemens Healthineers Q3 profit, cash flow fall on COVID test wind-up

TARRYTOWN, N.Y.--(BUSINESS WIRE)--The newest addition to the Siemens Healthineers Atellica in vitro diagnostics portfolio, the Atellica CI Analyzer1 for immunoassay and clinical chemistry testing, has received FDA clearance and is now available in many of the world's major markets. Labs operating at low to medium testing volumes will benefit from competitive advantages that the analyzer offers, including improved turnaround time predictability, advanced reporting functionality, and focused safe.

Siemens Healthineers launches Atellica CI Analyzer, compact testing system to tackle lab challenges

Siemens Healthineers has been re-rated in recent months, as easing supply chain headwinds allow it to address the growing backlog. But expectations are high now, with the near-term guidance reaffirmed despite quarterly earnings numbers falling short. Further write-downs of the outsized goodwill balance pose additional downside risk to future earnings.

Siemens Healthineers: Still An Interesting MedTech Name But Now At A Premium

MONROE TOWNSHIP, N.J., OXFORD, England & MALVERN, Pa.--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, and PETNET Solutions Inc, A Siemens Healthineers Company, today announced the commercial availability of POSLUMA® (flotufolastat F 18) in the United States. POSLUMA (formerly referred to as to as 18F-rhPSMA-7.3) is an optimized, high-affinity radiohybrid (rh) Prostate-Specific Membr.

Blue Earth Diagnostics and PETNET Solutions Inc, A Siemens Healthineers Company, Announce U.S. Commercial Availability of POSLUMA® (Flotufolastat F 18) Injection for PET Imaging of Prostate Cancer

I looked at Siemens Healthineers in my last article back in March, which makes it suitable for an update at this time. Siemens Healthineers remains a solid company to look at for long-term investment - even if the company has outperformed and is more expensive now than before. I remain at a "BUY" on Healthineers - albeit at a somewhat reduced upside next to where I was a few months back.

Siemens Healthineers: Still A Company Worth Looking At

Siemens Healthineers AG (OTCPK:SEMHF) Q2 2023 Earnings Conference Call May 10, 2023 2:30 AM ET Company Participants Marc Koebernick - Head, Investor Relations Bernhard Montag - Chief Executive Officer Jochen Schmitz - Chief Financial Officer Conference Call Participants Veronika Dubajova - Citi Hassan Al-Wakeel - Barclays David Adlington - JPMorgan Graham Doyle - UBS Odysseas Manesiotis - Berenberg Falko Friedrichs - Deutsche Bank Robert Davies - Morgan Stanley Sezgi Oezener - HSBC Operator Good morning, ladies and gentlemen, and welcome to Siemens Healthineers Conference Call. As a reminder, this conference is being recorded.

Siemens Healthineers AG (SEMHF) Q2 2023 Earnings Call Transcript

WASHINGTON--(BUSINESS WIRE)--A partnership between Siemens, Siemens Healthineers, and the University of California, San Francisco has proven medical centers can achieve significant carbon reduction and cost savings by turning off or putting MRIs into the lowest power setting when not in use. The findings, featured in a new Radiology study, can help the healthcare sector meaningfully reduce its carbon footprint, one that accounts for 4.4% of global carbon emissions. Working in tandem with UCSF,.

Siemens, Siemens Healthineers and UCSF research partnership proves significant energy, cost and emission reduction in MRI machine operation

ATLANTA--(BUSINESS WIRE)--Cognosos – a leading provider of real-time location services (RTLS)–today announced it has been selected by Siemens Healthineers to provide real-time asset tracking and intelligence for hospitals and healthcare systems. With this strategic relationship, Siemens Healthineers becomes an important reseller of the Cognosos portfolio of products and services.

Cognosos to Provide Siemens Healthineers with Next-Generation Technology to Power Real-Time Location Services for its Customer Network of Hospitals and Healthcare Facilities

I've often reviewed Siemens as a business - and also written about some of its various arms, but not reviewed Healthineers as of yet. This changes today. I'm going to be reviewing Siemens Healthineers and discuss its attraction as an investment.

Siemens Healthineers: Undervalued Quality, To Some Degree

HAMAMATSU, Japan , March 6, 2023 /PRNewswire/ -- Hamamatsu, a leading manufacturer of photonics devices, including whole slide scanners for digital pathology, today announced a multi-year distribution agreement with Siemens Healthineers. Under the agreement, Hamamatsu will provide NanoZoomer* whole slide scanners to support Siemens Healthineers expansion into digital pathology in the Americas and Europe.

Hamamatsu and Siemens Healthineers announce the distribution of the whole slide scanners to clinical markets

Hospital capital spending demand is strong, but Siemens Healthineers posted a small yet broad miss across its major business units for the fiscal first quarter. Imaging is performing well and Varian and Advanced Therapies were compromised by supply chain challenges, but core underperformance in Diagnostics is an ongoing issue.

Siemens Healthineers: Robust Equipment Demand, But With Some Ongoing Internal Challenges

Siemens Healthineers AG (OTCPK:SEMHF) Q1 2023 Earnings Conference Call February 2, 2023 2:30 AM ET Company Participants Marc Koebernick - Head of Investor Relations Bernd Montag - Chief Executive Officer Jochen Schmitz - Chief Financial Officer Conference Call Participants Hassan Al-Wakeel - Barclays Veronika Dubajova - Citi Graham Doyle - UBS David Adlington - JPMorgan Sezgi Oezener - HSBC Robert Davies - Morgan Stanley Operator Good morning, ladies and gentlemen, and welcome to Siemens Healthineers Conference Call. As a reminder, this conference is being recorded.

Siemens Healthineers AG (SEMHF) Q1 2023 Earnings Call Transcript

Siemens Healthineers AG expects strong growth in both revenue and earnings per share through fiscal 2025. The company pays a dividend and buys back shares; the dividend yield is currently about 1.9% and the dividend per share increased 12% over the past year.

Siemens Healthineers: Valuation Too High

General Electric

Medtronic

Siemens Healthineers AG and General Electric Co's healthcare business are weighing a potential acquisition of two units being spun off by Medtronic Plc, Bloomberg news reported on Thursday, citing people familiar with the matter.

Siemens Healthineers, GE Healthcare eye Medtronic units - Bloomberg News

CHARLOTTE, N.C. & MALVERN, Pa.--( BUSINESS WIRE )--Siemens Healthineers and Atrium Health, a leading nonprofit health provider known for its top-ranked pediatric, cancer and heart care programs, have announced a multi-year Value Partnership1 agreement. This strategic agreement will focus on driving access to care in Atrium Health's service region across the southeastern U.S., improving health equity and enhancing economic mobility. Atrium Health will purchase $140 million in Siemens Healthineers devices and equipment, including advanced imaging technology, radiation oncology and precision endovascular robotics.

Siemens Healthineers, Atrium Health Enter Multi-Year Value Partnership to Improve Health Care Capabilities, Access and Equity

Siemens Healthineers AG (OTCPK:SEMHF) Q4 2022 Earnings Conference Call November 9, 2022 2:30 AM ET Company Participants Marc Koebernick - Head, IR Bernd Montag - President, CEO and Chairman Jochen Schmitz - CFO Conference Call Participants Hassan Al-Wakeel - Barclays David Adlington - JPMorgan James Vane-Tempest - Jefferies Graham Doyle - UBS Julien Dormois - BNP Paribas Exane Veronika Dubajova - Citi Odysseas Manesiotis - Berenberg Robert Davies - Morgan Stanley Falko Friedrichs - Deutsche Bank Sezgi Oezener - HSBC Ed Ridley-Day - Redburn Operator Good morning, ladies and gentlemen, and welcome to Siemens Healthineers' Conference Call. As a reminder, this conference is being recorded.

Siemens Healthineers AG (SEMHF) CEO Bernd Montag on Q4 2022 Results - Earnings Call Transcript

Siemens Healthineers on Wednesday posted rising earnings and revenue for the fourth quarter of its fiscal year that beat expectations, driven by the imaging division.

News for Siemens Healthineers AG Stock (SMMNY)